8-K current report · filed Nov 12, 2026

Oncology Institute, Inc. (TOI) 8-K Current Report: November 12, 2026

Item 7.01Item EX-99.1TOI overview

Short answer

Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated investor presentation supersedes the prior Exhibit 99.1 presentation.

Oncology Institute, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated investor presentation supersedes the prior Exhibit 99.1 presentation
  • Revised materials intended for investor meetings, potentially updating Starling Oncology’s strategic and financial messaging
  • Investors should review Exhibit 99.1 for the substantive changes

Item EX-99.1 · Exhibit EX-99.1

  • Investor presentation highlights Starling’s oncology value-based-care platform, combining capitated care, fee-for-service, specialty pharmacy, and clinical services
  • FY2026 revenue guidance $650M-$660M, with Adjusted EBITDA guidance $4M-$6M and free cash flow guidance $5M-$10M
  • 3Q26 revenue $170M, up 24% YoY, with Adjusted EBITDA $3.4M versus $(3.5)M in 3Q25
  • Specialty pharmacy revenue $109M, up 44% YoY, with 24% gross margin
  • Medical loss ratio 81%, down 400 basis points sequentially, supporting improving economics in delegated contracts

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Oncology Institute, Inc. 8-K filings

Get the next TOI 8-K as it lands

Follow TOI for push alerts, or ask the research agent what this filing means.